Achilles
Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients
Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year
CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication
Non-small cell lung cancer accounts for up to 90% of all lung cancer cases
AstraZeneca shares late-stage results for Tagrisso combination in lung cancer
An estimated 2.4 million people globally are diagnosed with lung cancer each year
AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer
Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year
FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer
ROS1-positive non-small cell lung cancer accounts for approximately 2% of new NSCLC cases
MHRA approves SFL’s Aumseqa to treat EGFR-mutated lung cancer in adults
Approximately 43,000 people are diagnosed with lung cancer every year in the UK
Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC
Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection
Johnson & Johnson’s subcutaneous Rybrevant granted EC approval to treat NSCLC
It is hoped that the formulation will improve the treatment experience for patients
AstraZeneca’s Imfinzi regimen receives EC approval to treat resectable NSCLC
More than 450,000 people are diagnosed with lung cancer every year in Europe
BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer
Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection
J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer
The regimen was approved by the MHRA earlier this month to treat EGFR-mutated NSCLC
J&J’s Lazcluze/Rybrevant combination granted MHRA approval for lung cancer
Approximately 47,000 people are diagnosed with lung cancer every year in the UK